Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

The murky path to drug discovery in ALS becomes clearer.

Gordon PH.

Lancet Neurol. 2013 Nov;12(11):1037-8. doi: 10.1016/S1474-4422(13)70224-2. Epub 2013 Sep 23. No abstract available. Erratum in: Lancet Neurol. 2013 Dec;12(12):1133.

PMID:
24067399
2.

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.

Gribkoff VK, Bozik ME.

CNS Neurosci Ther. 2008 Fall;14(3):215-26. doi: 10.1111/j.1755-5949.2008.00048.x. Review.

PMID:
18801114
3.

Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis.

Terro F, Lesort M, Viader F, Ludolph A, Hugon J.

Neuroreport. 1996 Aug 12;7(12):1970-2.

PMID:
8905705
4.

Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients.

Jacob S, Poeggeler B, Weishaupt JH, Sirén AL, Hardeland R, Bähr M, Ehrenreich H.

J Pineal Res. 2002 Oct;33(3):186-7. No abstract available.

PMID:
12220335
5.
6.

[Treatment of amyotrophic lateral sclerosis (ALS)].

Lund-Olesen K.

Ugeskr Laeger. 1999 Mar 8;161(10):1433. Danish. No abstract available.

PMID:
10085759
7.

Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment.

Pattee GL, Post GR, Gerber RE, Bennett JP Jr.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Jun;4(2):90-5.

PMID:
14506939
8.

Drug therapy for amyotrophic lateral sclerosis: Where are we now?

Carter GT, Krivickas LS, Weydt P, Weiss MD, Miller RG.

IDrugs. 2003 Feb;6(2):147-53. Review.

PMID:
12789618
9.

R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.

Wang H, Larriviere KS, Keller KE, Ware KA, Burns TM, Conaway MA, Lacomis D, Pattee GL, Phillips LH 2nd, Solenski NJ, Zivkovic SA, Bennett JP Jr.

Amyotroph Lateral Scler. 2008 Feb;9(1):50-8. doi: 10.1080/17482960701791234.

PMID:
18270879
10.

Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets.

Bosco DA, Landers JE.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):779-90. Review.

PMID:
20942785
11.

Therapeutic advances in amyotrophic lateral sclerosis.

Louvel E, Hugon J, Doble A.

Trends Pharmacol Sci. 1997 Jun;18(6):196-203. Review.

PMID:
9226998
12.

Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy.

Weiss MD, Weydt P, Carter GT.

Expert Opin Pharmacother. 2004 Apr;5(4):735-46. Review. Erratum in: Expert Opin Pharmacother. 2004 May;5(5):1231.

PMID:
15102560
13.

Antioxidant therapy in ALS.

Pioro EP.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1 Suppl 4:5-12; discussion 13-5. Review. No abstract available.

PMID:
11466960
14.

Novel trends in orphan market drug discovery: amyotrophic lateral sclerosis as a case study.

Clark JE, Brennan A, Ramesh TM, Heywood JA.

Front Biosci. 2002 Aug 1;7:c83-96. Review.

PMID:
12133810
15.
16.

Creatine and coenzyme Q10 in the treatment of ALS.

Strong MJ, Pattee GL.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1 Suppl 4:17-20. Review. No abstract available.

PMID:
11466954
17.

Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.

Gladman M, Cudkowicz M, Zinman L.

Curr Opin Neurol. 2012 Dec;25(6):735-42. doi: 10.1097/WCO.0b013e32835a309d. Review.

PMID:
23160423
18.

Report on the ALS Association's drug discovery workshop.

Robinson R, Brujin LI.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Mar;14(2):81-4. doi: 10.3109/21678421.2012.734519. Epub 2012 Oct 22. No abstract available.

PMID:
23134504
19.

Drug therapy in amyotrophic lateral sclerosis.

Murray B, Mitsumoto H.

Adv Neurol. 2002;88:63-82. Review. No abstract available.

PMID:
11908237
20.

The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies.

Gurney ME.

J Neurol Sci. 1997 Oct;152 Suppl 1:S67-73. Review.

PMID:
9419057

Supplemental Content

Support Center